926 related articles for article (PubMed ID: 24517065)
21. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats.
Mai QG; Zhang ZM; Xu S; Lu M; Zhou RP; Zhao L; Jia CH; Wen ZH; Jin DD; Bai XC
J Cell Biochem; 2011 Oct; 112(10):2902-9. PubMed ID: 21618594
[TBL] [Abstract][Full Text] [Related]
22. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity.
Lossdörfer S; Schwartz Z; Wang L; Lohmann CH; Turner JD; Wieland M; Cochran DL; Boyan BD
J Biomed Mater Res A; 2004 Sep; 70(3):361-9. PubMed ID: 15293309
[TBL] [Abstract][Full Text] [Related]
23. Increased OPG/RANKL ratio in the conditioned medium of soybean-treated osteoblasts suppresses RANKL-induced osteoclast differentiation.
Park K; Ju WC; Yeo JH; Kim JY; Seo HS; Uchida Y; Cho Y
Int J Mol Med; 2014 Jan; 33(1):178-84. PubMed ID: 24248634
[TBL] [Abstract][Full Text] [Related]
24. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
25. [Adiponectin regulates the expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand in human osteoblast].
Zhang XM; Xie H; Yuan LQ; Luo XH; Liao EY
Zhonghua Yi Xue Za Zhi; 2008 Jun; 88(22):1562-5. PubMed ID: 18956641
[TBL] [Abstract][Full Text] [Related]
26. Long chain polyunsaturated fatty acids alter membrane-bound RANK-L expression and osteoprotegerin secretion by MC3T3-E1 osteoblast-like cells.
Poulsen RC; Wolber FM; Moughan PJ; Kruger MC
Prostaglandins Other Lipid Mediat; 2008 Feb; 85(1-2):42-8. PubMed ID: 18077200
[TBL] [Abstract][Full Text] [Related]
27. Pioglitazone affects the OPG/RANKL/RANK system and increase osteoclastogenesis.
Xu F; Dong Y; Huang X; Chen P; Guo F; Chen A; Huang S
Mol Med Rep; 2016 Sep; 14(3):2289-96. PubMed ID: 27430581
[TBL] [Abstract][Full Text] [Related]
28. Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions.
Fioramonti M; Santini D; Iuliani M; Ribelli G; Manca P; Papapietro N; Spiezia F; Vincenzi B; Denaro V; Russo A; Tonini G; Pantano F
Oncotarget; 2017 Mar; 8(12):20113-20121. PubMed ID: 28223547
[TBL] [Abstract][Full Text] [Related]
29. Production of IL-7 is increased in ovariectomized mice, but not RANKL mRNA expression by osteoblasts/stromal cells in bone, and IL-7 enhances generation of osteoclast precursors in vitro.
Sato T; Watanabe K; Masuhara M; Hada N; Hakeda Y
J Bone Miner Metab; 2007; 25(1):19-27. PubMed ID: 17187190
[TBL] [Abstract][Full Text] [Related]
30. Membrane-bound receptor activator of NFκB ligand (RANKL) activity displayed by osteoblasts is differentially regulated by osteolytic factors.
Singh PP; van der Kraan AG; Xu J; Gillespie MT; Quinn JM
Biochem Biophys Res Commun; 2012 May; 422(1):48-53. PubMed ID: 22561018
[TBL] [Abstract][Full Text] [Related]
31. Expression profile of osteoprotegerin, RANK and RANKL genes in the femoral head of patients with avascular necrosis.
Samara S; Dailiana Z; Chassanidis C; Koromila T; Papatheodorou L; Malizos KN; Kollia P
Exp Mol Pathol; 2014 Feb; 96(1):9-14. PubMed ID: 24200492
[TBL] [Abstract][Full Text] [Related]
32. Differentiation of osteoprogenitor cells is affected by trauma-haemorrhage.
Neunaber C; Yesilkaya P; Pütz C; Krettek C; Hildebrand F
Injury; 2013 Oct; 44(10):1279-84. PubMed ID: 23773407
[TBL] [Abstract][Full Text] [Related]
33. IL-3 Differentially Regulates Membrane and Soluble RANKL in Osteoblasts through Metalloproteases and the JAK2/STAT5 Pathway and Improves the RANKL/OPG Ratio in Adult Mice.
Singh K; Piprode V; Mhaske ST; Barhanpurkar-Naik A; Wani MR
J Immunol; 2018 Jan; 200(2):595-606. PubMed ID: 29203513
[TBL] [Abstract][Full Text] [Related]
34. Osteoclast differentiation by RANKL and OPG signaling pathways.
Udagawa N; Koide M; Nakamura M; Nakamichi Y; Yamashita T; Uehara S; Kobayashi Y; Furuya Y; Yasuda H; Fukuda C; Tsuda E
J Bone Miner Metab; 2021 Jan; 39(1):19-26. PubMed ID: 33079279
[TBL] [Abstract][Full Text] [Related]
35. Puerarin prevents bone loss in ovariectomized mice and inhibits osteoclast formation in vitro.
Yuan SY; Sheng T; Liu LQ; Zhang YL; Liu XM; Ma T; Zheng H; Yan Y; Ishimi Y; Wang XX
Chin J Nat Med; 2016 Apr; 14(4):265-269. PubMed ID: 27114313
[TBL] [Abstract][Full Text] [Related]
36. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
[TBL] [Abstract][Full Text] [Related]
37. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.
Kanatani M; Sugimoto T; Sowa H; Kobayashi T; Kanzawa M; Chihara K
J Cell Physiol; 2004 Oct; 201(1):17-25. PubMed ID: 15281085
[TBL] [Abstract][Full Text] [Related]
38. Gu Ling Pian, a traditional Chinese medicine, regulates function and OPG/RANKL synthesis of osteoblasts via the p38 MAPK pathway.
Zhao Y; Li J; Liu Y; Yu KQ; Zhang J; Chen XG
J Pharm Pharmacol; 2007 Aug; 59(8):1167-73. PubMed ID: 17725861
[TBL] [Abstract][Full Text] [Related]
39. Alteration of bone cell function by RANKL and OPG in different in vitro models.
Lin JM; Callon KE; Lin CQ; Bava U; Zheng MH; Reid IR; Cornish J
Eur J Clin Invest; 2007 May; 37(5):407-15. PubMed ID: 17461987
[TBL] [Abstract][Full Text] [Related]
40. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]